Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
06-08 June, 2025
Not Confirmed
Not Confirmed
09-11 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
06-08 June, 2025
Industry Trade Show
Not Confirmed
09-11 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
23 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-to-present-updated-phase-1-monotherapy-data-on-gv20-0251-at-the-asco-annual-meeting-2025-302463357.html
27 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-announces-collaboration-agreement-with-mitsubishi-tanabe-pharma-corporation-to-develop-novel-antibody-drug-conjugates-302411169.html
16 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-presents-promising-phase-1-monotherapy-data-on-novel-checkpoint-inhibitor-gv20-0251-at-esmo-congress-2024-302247149.html
21 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-to-present-clinical-data-on-gv20-0251-at-the-esmo-congress-2024-302225841.html
24 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-announces-publication-in-cell-highlighting-the-discovery-of-igsf8-as-an-innate-immune-checkpoint-and-cancer-immunotherapy-target-302126064.html
18 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-announces-clinical-trial-collaboration-to-evaluate-gv20-0251-a-first-in-class-antagonist-antibody-against-the-novel-immune-checkpoint-igsf8-in-combination-with-keytruda-pembrolizumab-302120896.html
ABOUT THIS PAGE